The treatment landscape for hematologic malignancies has changed since the recent approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T). Moreover, more than 600 active trials are currently ongoing. However, early enthusiasm should be tempered since several issues are still unsolved and represent the challenges for the coming years. The lack of initial responses and early relapse are some hurdles to be tackled. Moreover, new strategies are needed to increase the safety profile or shorten the manufacturing process during CAR-T cells therapy production. Nowadays, most clinically evaluated CAR-T cells products are derived from autologous immune cells. The use of allogeneic CAR-T cells products generated using cells from healthy donors has the potential to change the scenario and overcome many of these limitations. In addition, CAR-T cells carry a high price tag, and there is an urgent need to understand how to pay for these therapies as many of today's current payment systems do not feature the functionality to address the reimbursement gap. Finally, the clinical experience with CAR-T cells for solid tumors has been less encouraging, and development in this setting is desirable.

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon / Martino, Massimo; Naso, Virginia; Loteta, Barbara; Canale, Filippo Antonio; Pugliese, Marta; Alati, Caterina; Musuraca, Gerardo; Nappi, Davide; Gaimari, Anna; Nicolini, Fabio; Mazza, Massimiliano; Bravaccini, Sara; Derudas, Daniele; Martinelli, Giovanni; Cerchione, Claudio. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - ELETTRONICO. - 23:21(2022), pp. 13332.1-13332.10. [10.3390/ijms232113332]

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Musuraca, Gerardo;Gaimari, Anna;Bravaccini, Sara;Martinelli, Giovanni;
2022

Abstract

The treatment landscape for hematologic malignancies has changed since the recent approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T). Moreover, more than 600 active trials are currently ongoing. However, early enthusiasm should be tempered since several issues are still unsolved and represent the challenges for the coming years. The lack of initial responses and early relapse are some hurdles to be tackled. Moreover, new strategies are needed to increase the safety profile or shorten the manufacturing process during CAR-T cells therapy production. Nowadays, most clinically evaluated CAR-T cells products are derived from autologous immune cells. The use of allogeneic CAR-T cells products generated using cells from healthy donors has the potential to change the scenario and overcome many of these limitations. In addition, CAR-T cells carry a high price tag, and there is an urgent need to understand how to pay for these therapies as many of today's current payment systems do not feature the functionality to address the reimbursement gap. Finally, the clinical experience with CAR-T cells for solid tumors has been less encouraging, and development in this setting is desirable.
2022
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon / Martino, Massimo; Naso, Virginia; Loteta, Barbara; Canale, Filippo Antonio; Pugliese, Marta; Alati, Caterina; Musuraca, Gerardo; Nappi, Davide; Gaimari, Anna; Nicolini, Fabio; Mazza, Massimiliano; Bravaccini, Sara; Derudas, Daniele; Martinelli, Giovanni; Cerchione, Claudio. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - ELETTRONICO. - 23:21(2022), pp. 13332.1-13332.10. [10.3390/ijms232113332]
Martino, Massimo; Naso, Virginia; Loteta, Barbara; Canale, Filippo Antonio; Pugliese, Marta; Alati, Caterina; Musuraca, Gerardo; Nappi, Davide; Gaimari, Anna; Nicolini, Fabio; Mazza, Massimiliano; Bravaccini, Sara; Derudas, Daniele; Martinelli, Giovanni; Cerchione, Claudio
File in questo prodotto:
File Dimensione Formato  
ijms-23-13332.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 603.15 kB
Formato Adobe PDF
603.15 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/962670
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact